Status:
TERMINATED
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Advanced Non-Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patient...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced measurable or evaluable solid tumors unresponsive to currently available therapies, or for which there is no curative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 and 1
- Life expectancy more than12 weeks
- Adequate bone marrow, liver and renal function
Exclusion
- Known brain metastasis
- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of start of screening procedures
- Major surgical procedure within 4 weeks of start of screening procedures
- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00915278
Start Date
September 1 2009
End Date
January 1 2013
Last Update
April 4 2014
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111
2
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-5536
3
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-7610
4
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232